All In Biotech

Drug Trial Radar · NCT06666413

China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

A Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Avalglucosidase Alfa in Chinese Participants With Infantile-onset Pompe Disease (IOPD)

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

13

Planned (sponsor's estimate)

Start

May 7, 2025

Primary completion

May 2, 2028

Study completion May 2, 2028

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single group, 52-week treatment, Phase 4, open-label, single-arm study to assess the safety and efficacy of avalglucosidase alfa IV infusion in male and female Chinese participants with IOPD who are treatment-naïve or were previously treated with ERT. Study details include: * The study duration: total study duration is approximately 64 weeks. * Screening period of up to 8 weeks * Treatment period of 52 weeks * Follow-up period of 4 weeks. (if the participant enrolls in another study or receives commercially available ERT, the follow-up period may be reduced from 4 to 2 weeks) * The number of visits will be 30, including 29 site visits and 1 phone call follow-up visit.

Conditions

  • Glycogen Storage Disease Type II
  • Pompe's Disease

Interventions

  • Avalglucosidase alfaDrug

    Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEs, SAEs, AESIs including IARs during the TE periodTime frame: From baseline to Week 56
  2. Abnormality in clinical laboratory, vital signs, and ECG parameters during the TE periodTime frame: From baseline to Week 56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number: 1560001

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.